• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Acute Occupational and Physical Therapy for COVID-19 Patients: A Retrospective Cohort Study
In March 2020, the World Health Organization (WHO) declared the novel coronavirus strain SARS-CoV2 (the virus causing COVID-19) a global pandemic.24 The severity of illness in those exhibiting symptoms ranges from mild (cough, shortness of breath, fatigue) to severe (acute respiratory distress syndrome (ARDS), thrombosis, stroke, and death).4,11 Patients have also acquired acute polyradiculoneuritis (Guillain Barre syndrome) at a disproportionately high rate, contributing to functional limitations that require specialized and intensive rehabilitation.
Source: Archives of Physical Medicine and Rehabilitation - July 31, 2022 Category: Rehabilitation Authors: Katie Coakley, Laura Friedman, Kaitlyn McLoughlin, Amy Wozniak, Paul Hutchison Tags: Original Research Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

A review of pathophysiology and neuropsychiatric manifestations of COVID-19
ConclusionThe neurological manifestations of the COVID-19 are varied and the data about this continue to evolve as the pandemic continues to progress.
Source: Journal of Neurology - June 2, 2020 Category: Neurology Source Type: research